An agentic AI system enhances clinical detection of immunotherapy toxicities: a multi-phase validation study
Immune-related adverse events (irAEs) affect up to 40% of patients receiving immune checkpoint inhibitors, yet their identification depends on laborious and inconsistent manual chart review. Here we developed and evaluated an agentic large language model system to extract the presence, temporality, severity grade, attribution, and certainty of six irAE types from clinical notes. Retrospectively (263 notes), the system achieved macro-averaged F1 of 0.92 for detection and 0.66 for multi-class severity grading; self-consistency improved F1 by 0.14. The best-performing configuration cost approximately $0.02 per note. In prospective silent deployment over three months (884 notes), detection F1 was 0.72-0.79. In a randomized crossover study of clinical trial staff (17 participants, 316 observations), agentic assistance reduced annotation time by 40% (P < 0.001), increased complete-match accuracy (OR 1.45; 95% CI 1.01-2.09; P = 0.045), and improved inter-annotator agreement (Krippendorff's α from 0.22-0.51 to 0.82-0.85). These results demonstrate that agentic AI coupled with human verification could enhance efficiency, performance, and consistency for irAE assessment.
Authors
- Katherine C. Kellogg (ORCID: https://orcid.org/0000-0003-4372-3498)
- Bingxue K. Zhai
- Tanna L. Nelson
- Matthew J. Hadfield (ORCID: https://orcid.org/0000-0002-8768-0082)
- David Kozono (ORCID: https://orcid.org/0000-0002-8916-396X)
- Jeremy Warner (ORCID: https://orcid.org/0000-0002-1732-4154)
- Elad Sharon (ORCID: https://orcid.org/0000-0002-2512-3539)
- A. Gusev
- Jack Gallifant
- A.P. Warrington
- Kee-Young Shin
- Bingyang Ye
- Benjamin H. Kann
- Jonathan D. Schoenfeld
- Harry H. Hochheiser
- Paul Catalano
- Guergana K. Savova
- Raymond H. Mak
- Patrick F. Doyle
- Paul Nguyen
- Danielle Bitterman
- Hugo JWL Aerts
- Biagio Ricciuti
- David C. Christiani
- Shan Chen
- Joyce Guo
Institutions
- Boston Children's Hospital (US)
- Harvard University (US)
- University of Pittsburgh (US)
- Brown University (US)
- Rhode Island Hospital (US)
- Maastricht University (NL)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Mass General Brigham (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-03-02
- DOI
- https://doi.org/10.64898/2026.02.26.26347179
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Patient-Centered Outcomes Research Institute
- Brown University
- Varian Medical Systems
- Regeneron Pharmaceuticals
- Siemens Medical Solutions USA
- ViewRay
- National Institutes of Health
- Genentech
- EMD Serono
- National Cancer Institute